Lacosamida Fresenius Kabi

Lacosamide, the active ingredient in Lacosamida Fresenius Kabi, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy, including adults and children who require rapid or controlled plasma levels. The formulation enables precise dosing in acute‑care settings.

GNH USA supplies Lacosamida Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and healthcare institutions worldwide.

Lacosamide is an anticonvulsant used in the management of epilepsy, specifically targeting partial‑onset seizures.

Partial‑onset seizures (focal seizures): Reduces seizure frequency as add‑on therapy. Refractory focal epilepsy: Provides an additional mechanism when other agents are insufficient. Adjunctive therapy in epilepsy: Enhances overall seizure control when combined with other antiepileptic drugs.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness. - Nausea: Mild gastrointestinal upset. - Headache: Occasional tension‑type headache. - Fatigue: Generalized tiredness. - Diplopia: Temporary blurred vision. - Somnolence: Increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: Mood changes requiring monitoring. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: Marked decrease in breathing effort. - Hepatic enzyme elevation: Significant increase in liver function tests. - Anaphylaxis: Acute allergic reaction with hypotension and airway compromise.

Lacosamide requires careful clinical monitoring due to its pharmacologic profile.

Renal impairment: Adjust monitoring as drug is primarily renally excreted. Hepatic impairment: Use with caution; monitor liver function. Cardiac conduction disorders: Monitor ECG for PR‑interval prolongation. Pregnancy: Safety unknown; weigh potential risks against benefits. Concomitant CNS depressants: May increase sedation. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Lacosamide may interact with several medications; clinicians should assess the relevance of each.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): May exacerbate PR‑interval prolongation. - Carbamazepine: Can reduce lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): May lower lacosamide exposure.

Moderate Interactions (Monitor Closely): - Other sodium‑channel blockers (e.g., phenytoin): Additive CNS effects. - Opioids: Potential for increased sedation and respiratory depression. - Alcohol: Enhanced dizziness and impairment.